Power to the Patients

A podcast about doing great research.
From science to operations.

Go back

Season 3

S
3
•
6
•
June 19, 2025

Gerard Sanacora, Professor at Yale, on glutamate, GABA, and the next era of depression treatment

Listen to episode
S
3
•
5
•
June 12, 2025

Dina Burkitbayeva, CEO of Freedom Biosciences and co-founder of PsyMed Ventures

Listen to episode
S
3
•
4
•
April 28, 2025

Joel Raskin, CMO of Arrivo Bio discusses unlocking the future of psychiatry

Listen to episode
S
3
•
3
•
May 15, 2025

Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass General Center on the Neuroscience of Psychedelics

Listen to episode
S
3
•
2
•
May 13, 2025

Spyros Papapetropoulos: CEO of Neuphoria

Listen to episode
S
3
•
1
•
April 30, 2025

Steven Gourlay: CEO of Actinogen

Listen to episode
S
3
•
•
May 7, 2025

Husseini Manji on Developing Spravato

Listen to episode

Season 2

S
2
•
15
•

John Krystal, Chair of Psychiatry at Yale: Advancing Ketamine Research & Psychiatry at Yale

Listen to episode
S
2
•
14
•

Shawn Singh, CEO of Vistagen: Next-gen treatments for anxiety and depression disorders

Listen to episode
S
2
•
13
•

Dr. Jordan Smoller, Harvard Medical School on AI for Clinical Trials

Listen to episode
S
2
•
12
•

Anthony Yanni, Global Head of Patient Centricity at Astellas, on building a framework for patient-centered trials

Listen to episode
S
2
•
11
•

Ray Sanchez, Former Cerevel CMO: Unraveling Mysteries of the Brain Through Neuroscience Research

Listen to episode
S
2
•
10
•

Amit Etkin, CEO of Alto Neuroscience: Harnessing Precision Medicine to Redefine Psychiatric Treatment

Listen to episode
S
2
•
9
•

Kabir Nath, CEO of Compass Pathways: Breaking New Ground with Psilocybin

Listen to episode
S
2
•
8
•

Katie Baca-Motes, Co-founder at Scripps Research: Bringing the Consumer Experience to Clinical Research

Listen to episode
S
2
•
7
•

Manish Agrawal, CEO of Sunstone Therapies: A New Frontier of Psychedelic Therapies

Listen to episode
S
2
•
6
•

Srinivas Rao, CEO of atai Life Sciences: A Pragmatic Approach to Psychedelic Drug Development

Listen to episode
S
2
•
5
•

Jessica Branning, former CEO of ClinCloud: Building a High-Recruiting Site in Alzheimer's

Listen to episode
S
2
•
4
•

Cosmo Feilding Mellen, CEO of Beckley Psytech: Why Beckley Psytech is Developing the Next Generation of Psychedelics

Listen to episode
S
2
•
3
•

Jeff Winton, Founder of Rural Minds: The Mental Health Epidemic in Rural America

Listen to episode
S
2
•
2
•

Doug Drysdale, CEO of Cybin: Going All In on Psilocybin for Depression

Listen to episode
S
2
•
1
•

Dan Karlin, Chief Medical Officer at MindMed: Psychedelics and the Future of Anxiety Relief

Listen to episode
S
2
•
16
•

Boehringer Ingelheim: Christine Sakdalan and Michael Jablonski

Listen to episode

Season 1

S
1
•
1
•
February 18, 2025

Patient-centered design with Scott Schliebner, former SVP at ICON

Listen to episode
S
1
•
2
•
February 18, 2025

Oncology Trial Strategy with Deb Kientop, VP Clinical Operations at Deka Biosciences

Listen to episode
S
1
•
3
•
February 18, 2025

Patient advocacy with Stephanie E. Saville, Foundation Manager for the Pediatric Retinal Research Foundation

Listen to episode
S
1
•
4
•
February 18, 2025

Exploring Technology and Patient Engagement in Clinical Trials with Bryan Wylie

Listen to episode
S
1
•
6
•
April 24, 2025

Victoria DiBiaso, VP & Global Head Patient Informed Development & Health Value Translation at Sanofi on patient-informed clinical trial development

Listen to episode

Subscribe to Power's Newsletter

Stay ahead with a new patient recruitment insight every week.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.